Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model

Subcutaneous Injection Performance in Yucatan Miniature Pigs with and without Human Hyaluronidase and Auto-injector Tolerability in Humans

(2021) Galen H. Shi et al.   AAPS PHARMSCITECH

Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery

(2021) Stephen P. Knowles et al.   Expert Opinion on Drug Delivery

Clinical strategies for optimizing infusion center care through a pandemic

(2020) Kirollos S Hanna et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20

(2019) Kenneth W. Locke et al.   DRUG DELIVERY

A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience

(2019) Bart J. F. van den Bemt et al.   DRUG DELIVERY

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

(2018) Beate Bittner et al.   BIODRUGS

High-concentration protein formulations: How high is high?

(2017) Patrick Garidel et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

(2016) M. Rummel et al.   ANNALS OF ONCOLOGY

Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase

(2016) Christopher C. DuFort et al.   BIOPHYSICAL JOURNAL

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer

(2016) Erwin De Cock et al.   Cancer Medicine

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

(2016) Erwin De Cock et al.   PLoS One

The Content and Size of Hyaluronan in Biological Fluids and Tissues

(2015) Mary K. Cowman et al.   Frontiers in Immunology

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

(2014) X. Pivot et al.   ANNALS OF ONCOLOGY

Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies

(2014) Richard L Wasserman   Immunotherapy

Hyaluronan: A simple polysaccharide with diverse biological functions

(2013) Kevin T. Dicker et al.   Acta Biomaterialia

Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer

(2012) Chris Wynne et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model

(2012) David W. Kang et al.   Drug Delivery and Translational Research